These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

339 related items for PubMed ID: 9816035

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
    Dhingra K, Frye D, Newman RA, Walters R, Theriault R, Fraschini G, Smith T, Buzdar A, Hortobagyi GN.
    Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A prospective, randomized Phase III trial comparing combination chemotherapy with cyclophosphamide, doxorubicin, and 5-fluorouracil with vinorelbine plus doxorubicin in the treatment of advanced breast carcinoma.
    Blajman C, Balbiani L, Block J, Coppola F, Chacon R, Fein L, Bonicatto S, Alvarez A, Schmilovich A, Delgado FM.
    Cancer; 1999 Mar 01; 85(5):1091-7. PubMed ID: 10091793
    [Abstract] [Full Text] [Related]

  • 6. Weekly paclitaxel improved pathologic response of primary chemotherapy compared with standard 3 weeks schedule in primary breast cancer.
    Qi M, Li JF, Xie YT, Lu AP, Lin BY, Ouyang T.
    Breast Cancer Res Treat; 2010 Aug 01; 123(1):197-202. PubMed ID: 20582466
    [Abstract] [Full Text] [Related]

  • 7. Phase I study of amonafide dosing based on acetylator phenotype.
    Ratain MJ, Mick R, Berezin F, Janisch L, Schilsky RL, Vogelzang NJ, Lane LB.
    Cancer Res; 1993 May 15; 53(10 Suppl):2304-8. PubMed ID: 8485716
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Phase II trial of a combination of vinorelbine, cyclophosphamide and 5-fluorouracil in the treatment of advanced breast cancer.
    Ardavanis A, Extra JM, Espié M, Cuvier C, Marty M.
    In Vivo; 1998 May 15; 12(5):559-62. PubMed ID: 9827368
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The impact of schedule on acute toxicity and dose-intensity of high-dose chemotherapy with epirubicin and cyclophosphamide plus colony stimulating factors in advanced breast cancer.
    De Placido S, Lauria R, Carlomagno C, Perrone F, De Laurentiis M, Gallo C, Martignetti A, Bellelli T, Limite G, Petrella G, Bianco AR.
    Int J Oncol; 1999 Aug 15; 15(2):339-46. PubMed ID: 10402245
    [Abstract] [Full Text] [Related]

  • 12. Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer.
    Saeki T, Nomizu T, Toi M, Ito Y, Noguchi S, Kobayashi T, Asaga T, Minami H, Yamamoto N, Aogi K, Ikeda T, Ohashi Y, Sato W, Tsuruo T.
    J Clin Oncol; 2007 Feb 01; 25(4):411-7. PubMed ID: 17179098
    [Abstract] [Full Text] [Related]

  • 13. Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma.
    Fornier MN, Seidman AD, Theodoulou M, Moynahan ME, Currie V, Moasser M, Sklarin N, Gilewski T, D'Andrea G, Salvaggio R, Panageas KS, Norton L, Hudis C.
    Clin Cancer Res; 2001 Dec 01; 7(12):3934-41. PubMed ID: 11751485
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer: final results.
    Rouëssé J, de la Lande B, Bertheault-Cvitkovic F, Serin D, Graïc Y, Combe M, Leduc B, Lucas V, Demange L, Nguyen TD, Castèra D, Krzisch C, Villet R, Mouret-Fourme E, Garbay JR, Noguès C, Centre René Huguenin Breast Cancer Group.
    Int J Radiat Oncol Biol Phys; 2006 Mar 15; 64(4):1072-80. PubMed ID: 16504757
    [Abstract] [Full Text] [Related]

  • 16. Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience.
    Muss HB, Berry DA, Cirrincione C, Budman DR, Henderson IC, Citron ML, Norton L, Winer EP, Hudis CA, Cancer and Leukemia Group B Experience.
    J Clin Oncol; 2007 Aug 20; 25(24):3699-704. PubMed ID: 17704418
    [Abstract] [Full Text] [Related]

  • 17. A phase II study of sequential 5-fluorouracil, epirubicin and cyclophosphamide (FEC) and paclitaxel in advanced breast cancer (Protocol PV BC 97/01).
    Riccardi A, Pugliese P, Danova M, Brugnatelli S, Grasso D, Giordano M, Bernardo G, Giardina G, Fava S, Montanari G, Pedrotti C, Trotti G, Rinaldi E, Poli MA, Tinelli C.
    Br J Cancer; 2001 Jul 20; 85(2):141-6. PubMed ID: 11461067
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial.
    Venturini M, Del Mastro L, Aitini E, Baldini E, Caroti C, Contu A, Testore F, Brema F, Pronzato P, Cavazzini G, Sertoli MR, Canavese G, Rosso R, Bruzzi P.
    J Natl Cancer Inst; 2005 Dec 07; 97(23):1724-33. PubMed ID: 16333028
    [Abstract] [Full Text] [Related]

  • 20. Phase III study of standard combination versus rotating regimen of induction chemotherapy in patients with hormone insensitive metastatic breast cancer: an Eastern Cooperative Oncology Group Intergroup Study (E3185).
    Pandya KJ, Hu P, Osborne CK, Falkson G, Tormey DC, Eastern Cooperative Oncology Group.
    Am J Clin Oncol; 2007 Apr 07; 30(2):113-25. PubMed ID: 17414459
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.